title: [Intra-arterial chemotherapy for invasive bladder cancer].
abstract: The present investigation was conducted to examine the effects of intra-arterial chemotherapy (IAC) for patients with invasive bladder cancer. A total of 37 patients were treated with IAC at Nara Medical University and its affiliated hospitals between January, 1993 and August, 1997. There were 27 patients in the poor risk group. The remaining 10 patients underwent anti-tumor IAC. Thirty of the 37 patients received chemotherapeutic agents via a reservoir, and the remaining 7 patients received a one-shot injection of agents followed by transcatheter arterial embolization (TAE). In the reservoir group, there were 18 patients who received IAC in combination with radiation therapy. As a result, reduction of tumor size was noted in 53%, and the 3-year cause-specific survival rate was 54% in all cases. There was a significant difference in the 3-year survival rate between the radiation-treated group and the group without radiation. The adverse events included anemia, leukopenia, thrombocytopenia and gastrointestinal symptoms, but none of them were severe. The results of the present study indicate that IAC is useful in the treatment of invasive bladder cancer for poor risk patients.
authors.affiliation: Department of Urology, Nara Medical University.
authors.forename: S
authors.initials: S
authors.lastname: Ozono
authors.forename: S C
authors.initials: SC
authors.lastname: Kim
authors.forename: K
authors.initials: K
authors.lastname: Takashima
authors.forename: Y
authors.initials: Y
authors.lastname: Tani
authors.forename: E
authors.initials: E
authors.lastname: Okajima
authors.forename: Y
authors.initials: Y
authors.lastname: Hirao
authors.forename: Y
authors.initials: Y
authors.lastname: Maruyama
authors.forename: A
authors.initials: A
authors.lastname: Iwai
authors.forename: S
authors.initials: S
authors.lastname: Samma
authors.forename: H
authors.initials: H
authors.lastname: Momose
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D004317:Doxorubicin; D002945:Cisplatin